BRPI0819598A2 - anticorpos para o antígeno pcrv da pseudomonas aeruginosa - Google Patents
anticorpos para o antígeno pcrv da pseudomonas aeruginosaInfo
- Publication number
- BRPI0819598A2 BRPI0819598A2 BRPI0819598A BRPI0819598A BRPI0819598A2 BR PI0819598 A2 BRPI0819598 A2 BR PI0819598A2 BR PI0819598 A BRPI0819598 A BR PI0819598A BR PI0819598 A BRPI0819598 A BR PI0819598A BR PI0819598 A2 BRPI0819598 A2 BR PI0819598A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- pseudomonas aeruginosa
- aeruginosa pcrv
- pcrv antigen
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99167907P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/085196 WO2009073631A2 (en) | 2007-11-30 | 2008-12-01 | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0819598A2 true BRPI0819598A2 (pt) | 2017-05-09 |
Family
ID=40527381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819598A BRPI0819598A2 (pt) | 2007-11-30 | 2008-12-01 | anticorpos para o antígeno pcrv da pseudomonas aeruginosa |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8044181B2 (pt) |
| EP (1) | EP2220117A2 (pt) |
| JP (1) | JP5781765B2 (pt) |
| KR (1) | KR20100097719A (pt) |
| CN (1) | CN101910197B (pt) |
| AU (1) | AU2008333985B2 (pt) |
| BR (1) | BRPI0819598A2 (pt) |
| CA (1) | CA2706732A1 (pt) |
| EA (1) | EA201000903A1 (pt) |
| IL (1) | IL206036A0 (pt) |
| MX (1) | MX2010005871A (pt) |
| NZ (1) | NZ586357A (pt) |
| SG (1) | SG186017A1 (pt) |
| WO (1) | WO2009073631A2 (pt) |
| ZA (1) | ZA201003852B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
| JP5444553B2 (ja) * | 2007-04-27 | 2014-03-19 | フェネックス インコーポレイテッド | 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| BRPI0906810A2 (pt) | 2008-01-10 | 2019-10-01 | Shionogi & Co | anticorpo contra pcrv |
| WO2010091189A1 (en) * | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| CN104119437A (zh) * | 2009-03-11 | 2014-10-29 | 盐野义制药株式会社 | 具有抗绿脓杆菌作用的人源化PcrV抗体 |
| CA2784033A1 (en) * | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| WO2012012571A1 (en) | 2010-07-21 | 2012-01-26 | Hans Zassenhaus | Biolayer interferometry measurement of biological targets |
| BR112013031485B1 (pt) | 2011-06-10 | 2022-06-14 | Medimmune, Llc | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais |
| BR112014011028B1 (pt) | 2011-11-07 | 2021-03-02 | Medimmune, Llc | anticorpo biespecífico, composição, e, uso da composição |
| SG11201404532XA (en) | 2012-03-02 | 2014-08-28 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| JP2015535005A (ja) * | 2012-11-06 | 2015-12-07 | メディミューン，エルエルシー | 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療 |
| EP3288974B1 (en) * | 2015-05-01 | 2020-11-04 | Inhibrx, Inc. | Type iii secretion system targeting molecules |
| NZ777930A (en) | 2015-07-16 | 2025-05-02 | Inhibrx Biosciences Inc | Multivalent and multispecific dr5-binding fusion proteins |
| EA201892525A1 (ru) | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
| SG11202008926RA (en) | 2018-03-14 | 2020-10-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| CN112955463B (zh) | 2018-08-01 | 2024-07-05 | 赛福伦有限责任公司 | 抗cxcr2抗体及其用途 |
| SG11202112462RA (en) * | 2019-06-11 | 2021-12-30 | Regeneron Pharma | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| CN118620074A (zh) * | 2020-06-01 | 2024-09-10 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US134098A (en) * | 1872-12-17 | Improvement in gage-cocks | ||
| US108565A (en) * | 1870-10-25 | Improvement in snow-plows | ||
| US225552A (en) * | 1880-03-16 | Disintegrating-mill | ||
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5219998A (en) * | 1990-06-04 | 1993-06-15 | Levin Robert H | Yeast-derived epidermal growth factor |
| GB9012995D0 (en) * | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| CA2267620A1 (en) | 1996-07-16 | 1998-01-22 | Andreas Pluckthun | Immunoglobulin superfamily domains and fragments with increased solubility |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| DE69930166T2 (de) * | 1998-11-25 | 2006-12-14 | MCW Research Foundation, Inc., Milwaukee | Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen |
| DE19918418C1 (de) * | 1999-04-23 | 2000-10-19 | Siegfried Mueller | Pflanzvorrichtung mit Halterung |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| DK1353688T3 (da) * | 2001-01-26 | 2007-04-10 | Mcw Res Found Inc | Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet |
| CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| EP1479695B1 (en) * | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| JP4782700B2 (ja) | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| US20060134098A1 (en) * | 2004-11-16 | 2006-06-22 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| WO2006122822A2 (en) | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | High-level expression of recombinant antibody in a mammalian host cell |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| CA2613691A1 (en) | 2005-07-05 | 2007-01-11 | Baker Medical Research Institute | Anticoagulation agent and uses thereof |
| US20080317710A1 (en) | 2006-02-22 | 2008-12-25 | University Of Zurich | Methods For Treating Autoimmune or Demyelinating Diseases |
| AR061171A1 (es) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch) |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
-
2008
- 2008-12-01 EP EP08856948A patent/EP2220117A2/en not_active Ceased
- 2008-12-01 BR BRPI0819598A patent/BRPI0819598A2/pt not_active IP Right Cessation
- 2008-12-01 JP JP2010536228A patent/JP5781765B2/ja not_active Expired - Fee Related
- 2008-12-01 MX MX2010005871A patent/MX2010005871A/es active IP Right Grant
- 2008-12-01 AU AU2008333985A patent/AU2008333985B2/en not_active Ceased
- 2008-12-01 SG SG2012085239A patent/SG186017A1/en unknown
- 2008-12-01 CN CN200880124705.7A patent/CN101910197B/zh not_active Expired - Fee Related
- 2008-12-01 KR KR1020107014345A patent/KR20100097719A/ko not_active Ceased
- 2008-12-01 WO PCT/US2008/085196 patent/WO2009073631A2/en not_active Ceased
- 2008-12-01 EA EA201000903A patent/EA201000903A1/ru unknown
- 2008-12-01 CA CA2706732A patent/CA2706732A1/en active Pending
- 2008-12-01 NZ NZ586357A patent/NZ586357A/xx not_active IP Right Cessation
- 2008-12-01 US US12/325,806 patent/US8044181B2/en not_active Expired - Fee Related
-
2010
- 2010-05-27 IL IL206036A patent/IL206036A0/en unknown
- 2010-05-28 ZA ZA2010/03852A patent/ZA201003852B/en unknown
-
2011
- 2011-10-11 US US13/271,146 patent/US8877191B2/en not_active Expired - Fee Related
-
2014
- 2014-10-08 US US14/509,437 patent/US20150030614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009073631A3 (en) | 2009-09-24 |
| EA201000903A1 (ru) | 2011-02-28 |
| ZA201003852B (en) | 2014-11-26 |
| IL206036A0 (en) | 2010-11-30 |
| JP2011505381A (ja) | 2011-02-24 |
| CN101910197A (zh) | 2010-12-08 |
| WO2009073631A2 (en) | 2009-06-11 |
| KR20100097719A (ko) | 2010-09-03 |
| CN101910197B (zh) | 2014-09-24 |
| MX2010005871A (es) | 2010-06-09 |
| EP2220117A2 (en) | 2010-08-25 |
| NZ586357A (en) | 2012-10-26 |
| US8044181B2 (en) | 2011-10-25 |
| US20120020986A1 (en) | 2012-01-26 |
| JP5781765B2 (ja) | 2015-09-24 |
| AU2008333985A1 (en) | 2009-06-11 |
| US20150030614A1 (en) | 2015-01-29 |
| US8877191B2 (en) | 2014-11-04 |
| CA2706732A1 (en) | 2009-06-11 |
| US20090191186A1 (en) | 2009-07-30 |
| SG186017A1 (en) | 2012-12-28 |
| AU2008333985B2 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0819598A2 (pt) | anticorpos para o antígeno pcrv da pseudomonas aeruginosa | |
| CY2021027I2 (el) | Σκευασματα αντισωματων anti-cd20 | |
| CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| DK2234600T3 (da) | Antistofformulering | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| HUE056626T2 (hu) | Antitestkészítmény | |
| PL3059246T3 (pl) | Zmodyfikowany region stały przeciwciała | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| PT2853545T (pt) | Anticorpo específico para ige | |
| BRPI0809677A2 (pt) | Anticorpos anti-ige | |
| NO344963B1 (no) | Humanisert antistoff | |
| DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
| EP2211903A4 (en) | CLL-1 ANTIBODY | |
| PT2195026E (pt) | Anticorpos anti-esclerostina | |
| BRPI0917204A2 (pt) | variantes estruturais de anticorpos para melhores características terapêuticas | |
| EP2324359A4 (en) | MONOCLONAL ANTIBODY STRO-4 | |
| BRPI0807991A2 (pt) | Anticorpos anti-il-23r elaborados. | |
| HUE050985T2 (hu) | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák | |
| CR10705A (es) | Anticuerpos para linfotoxina-alfa | |
| BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
| EP2172483A4 (en) | ANTI-MUC17 ANTIBODY | |
| EP2536834A4 (en) | ANTIBODY AGAINST SEROTYPE B-LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA | |
| BRPI0814111A2 (pt) | Anticorpo monoclonal citotóxico anticâncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |